The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?

  • Kwok, Seung-Ki (Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea)
  • Received : 2014.08.09
  • Accepted : 2014.08.12
  • Published : 2014.09.01
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Harris ED Jr. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-1289. https://doi.org/10.1056/NEJM199005033221805
  2. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003;302:875-878. https://doi.org/10.1126/science.1087061
  3. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH; Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011;63:1150-1158.
  4. Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012;64:617-629. https://doi.org/10.1002/art.33383
  5. Kremer JM, Cohen S, Wilkinson BE, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012;64:970-981. https://doi.org/10.1002/art.33419
  6. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-519. https://doi.org/10.1056/NEJMoa1112072
  7. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507. https://doi.org/10.1056/NEJMoa1109071
  8. Traynor K. FDA approves tofacitinib for rheumatoid arthritis. Am J Health Syst Pharm 2012;69:2120.
  9. Song GG, Bae SC, Lee YH. Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials. Korean J Intern Med 2014;29:656-663. https://doi.org/10.3904/kjim.2014.29.5.656
  10. Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014;370:2377-2386. https://doi.org/10.1056/NEJMoa1310476

Cited by

  1. The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions vol.12, pp.None, 2021, https://doi.org/10.3389/fphar.2021.680043